Premium
Rationale for treatment of hepatitis C virus infection in end‐stage renal disease patients who are not kidney transplant candidates
Author(s) -
AlRabadi Laith,
Box Terry,
Singhania Girish,
AlMarji Catreena,
Agarwal Adhish,
Hall Isaac,
Gordon Craig E.,
Tran Huy
Publication year - 2018
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/hdi.12656
Subject(s) - medicine , dialysis , hemodialysis , hepatitis c virus , hepatitis c , end stage renal disease , population , mortality rate , kidney disease , liver disease , intensive care medicine , immunology , virus , environmental health
Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV‐associated mortality are liver and cardiovascular‐related death. HCV‐infected HD patients have a higher prevalence of inflammation‐related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end‐stage renal disease. In the current era of highly effective direct‐acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis‐dependent patients who do not qualify for kidney transplantation. Currently, the most accepted regimens in this patient population include elbasvir/grazoprevir and glecaprevir/pibrentasvir